INTRODUCTION
There exists a large amount of epidemiologic and experimental data that suggests protease inhibitors have significant anticarcinogenic activity. 1 Several different types of protease inhibitors have been shown to inhibit the carcinogenic process, and on a molar basis those that inhibit chymotrypsin proteases have been the most effective. The soybean-derived chymotrypsin protease inhibitor known as the BowmanBirk inhibitor (BBI) has been the most widely studied. The structure of BBI is shown in F IGURE 1. It is a 71-amino-acid protein, and its structure was delineated in 1973. 2 The presence of five cystine bridges and both chymotrypsin and trypsin inhibitory sites is a unique feature of this molecule. A great deal of biochemical and biological work has been done with this protein, and it was recognized early that removal of the trypsin-inhibitable activity in soybeans was important as toxicity was largely related to this property of extracted proteins. It was also recognized that improper preparation resulted in ineffectiveness of the chymotrypsin-inhibitable function as well.
Eventually an extract from soybeans (BBI Concentrate  ) with the same ability as BBI to inhibit carcinogenesis was developed. 3 This was an important achievement since pure BBI is extremely expensive to obtain and its complex internal structure precludes a simple synthesis and, to date, the development of a biosynthetic engineering approach. BBIC is very stable, maintaining its chymotrypsin-inhibitable activity and its ability to inhibit transformation in vitro for over two years. 4 BBIC was approved by the FDA in 1992 for Investigational New Drug status and clinical trials were begun at that time. Our initial single-dose trial of the inhibitor demonstrated that the compound was well tolerated and without side effects, up to doses of 800 chymotrypsin inhibitory units (CIU), the highest dose tested. 5 
INTERMEDIATE MARKERS OF ORAL CARCINOGENESIS
The development of risk and surrogate intermediate markers for oral cancer has been a lengthy, difficult, and time-consuming process. 6, 7 We have investigated the role of a number of potential intermediate markers in oral carcinogenesis and have determined that proteolytic activities and neu oncogene expression are the most promising. We have reported that levels of proteolytic activities are increased 2-to 3-fold in oral mucosa cells of smokers and patients with oral leukoplakia or erythroplakia as compared to a non-smoking comparison group (see F IGURE 2). 8 Elevated levels were also found in patients with oral trauma and in diabetic patients as well as pregnant women. Since synthetic substrates are used to make these measurements reproducibility is high. Elevated levels of neu oncogene protein on cancer cells have been demonstrated in many epithelial cancers. 9 This molecule is a 185,000 dalton protein (p185) and is also referred to as c-erb-B-2 and Her-2. Serum neu protein is derived from the extracellular domain of the neu protein, which is released by proteolytic cleavage from the cell surface. A detailed study was done to determine the relationship between protease activity and neu protein levels in patients with oral leukoplakia. 10 A number of correlations were demonstrated: pretherapy serum and cellular neu protein levels were related, but the protease activity in oral mucosal cells did not correlate with either parameter. However, after BBIC treatment, activities of the cellular protease activity did correlate with serum neu levels (see F IGURE 3). A comparison of the changes in these markers pre-and post-treatment showed that the change in both serum and cellular neu protein correlated with changes in the protease activity. Overall, these results suggested that BBIC inhibited cleavage of the neu protein on the cell surface. This observation raises the possibility that by inhibiting the cleavage of neu protein on the cell surface BBI may work by preventing premalignant cells from escaping immunological surveillance and elimination of neu protein antigen.
Thirty-two patients were studied in our one-month, Phase IIa clinical trial of BBIC. 11 No consistent individual or group clinical side effects were detected and no effect on serum micronutrients demonstrated. Clinical response was determined by measurement and comparison of pre-and post-treatment individual lesion areas (as well as the summed total in each patient) and analysis of blinded clinical judgments of scrambled photographs. Two patients achieved a complete clinical response and an additional eight achieved a partial clinical response. The clinical response data are summarized in T ABLE 1. Overall, a 24.2% increase in total lesion area was observed following treatment and a linear fit of the dose-response relationship between dose of BBIC and decrease in total lesion area was evident. Additionally, no toxicity to the BBIC was detected, up to the maximal dose tested (1066 CIU). We also found that high pretreatment oral mucosal cell protease activity was associated with a greater decrease in protease activity after BBIC administration. Since both the level of protease activity and its response to BBIC affected response, we have modeled these parameters on clinical response and the optimized model is shown in F IGURE 4.
FUTURE STUDIES
The results from these series of clinical trials are highly encouraging. To date, BBIC has not produced detectable clinical or laboratory toxicity, even at the highest doses tested. We have shown evidence in a non-randomized trial for shrinkage of oral leukoplakia lesions and modulation of cellular protease and serum and cellular neu protein. We have now embarked on a longer placebo-controlled and randomized Phase IIb trial in which clinical lesion size, cellular protease activity, and serum and cellular neu protein levels will be measured and changes correlated. The broad involvement of the neu protein in many cancers suggests that exploration of BBIC in the prevention and treatment of other cancers would be worthwhile as well. 
